Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA

Cancer immunity

Nicolas van Baren⁸  Ferdy Lejeune^1,10  Pedro Romero²  Katharina Fleischhauer⁴  Donata Rimoldi¹  Marie Marchand⁵  Pascal Batard³  Alfred Zippelius⁹  Daniel E. Speiser⁹  Jean-Charles Cerottini²  Philippe Guillaume¹  Christine Geldhof⁹  Mikaël J. Pittet⁹  Danielle Liénard⁷  Maha Ayyoub⁹  Pierre-Yves Dietrich⁶ 

[1] Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland;Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, SwitzerlandDivision of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandDivision of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, SwitzerlandDivision of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland;Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandDeceasedDivision of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandDivision of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandDeceasedDeceasedDivision of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandDeceased;Division of Immunohematology and Blood Bank, Telethon Institute for Gene Therapy, Istituto Scientifico H.S. Raffaele, Milan, ItalyDivision of Immunohematology and Blood Bank, Telethon Institute for Gene Therapy, Istituto Scientifico H.S. Raffaele, Milan, ItalyDivision of Immunohematology and Blood Bank, Telethon Institute for Gene Therapy, Istituto Scientifico H.S. Raffaele, Milan, Italy;Ludwig Institute for Cancer Research, Brussels Branch, BelgiumMedical Oncology, Cliniques Universitaires St. Luc, Université de Louvain, Brussels, BelgiumLudwig Institute for Cancer Research, Brussels Branch, BelgiumLudwig Institute for Cancer Research, Brussels Branch, BelgiumMedical Oncology, Cliniques Universitaires St. Luc, Université de Louvain, Brussels, BelgiumMedical Oncology, Cliniques Universitaires St. Luc, Université de Louvain, Brussels, BelgiumLudwig Institute for Cancer Research, Brussels Branch, BelgiumMedical Oncology, Cliniques Universitaires St. Luc, Université de Louvain, Brussels, Belgium;Medical Oncology, University Hospital, Geneva, SwitzerlandMedical Oncology, University Hospital, Geneva, SwitzerlandMedical Oncology, University Hospital, Geneva, Switzerland;Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandMultidisciplinary Oncology Center, CHUV, Lausanne, SwitzerlandDivision of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandDivision of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandMultidisciplinary Oncology Center, CHUV, Lausanne, SwitzerlandMultidisciplinary Oncology Center, CHUV, Lausanne, SwitzerlandDivision of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandMultidisciplinary Oncology Center, CHUV, Lausanne, Switzerland;Ludwig Institute for Cancer Research, Brussels Branch, BelgiumLudwig Institute for Cancer Research, Brussels Branch, BelgiumLudwig Institute for Cancer Research, Brussels Branch, Belgium;Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandDivision of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandDivision of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland;Multidisciplinary Oncology Center, CHUV, Lausanne, SwitzerlandMultidisciplinary Oncology Center, CHUV, Lausanne, SwitzerlandMultidisciplinary Oncology Center, CHUV, Lausanne, Switzerland

关键词: clinical trial;    melanoma;    vaccination;    Melan-A peptide;    immunological adjuvants;    immunological monitoring;   

DOI  :  

学科分类：肿瘤学

来源: Cancer immunity

【 授权许可】

Unknown